

# Sabrina Noel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8044547/publications.pdf>

Version: 2024-02-01

28  
papers

1,175  
citations

489802

18  
h-index

591227

27  
g-index

28  
all docs

28  
docs citations

28  
times ranked

2063  
citing authors

#	ARTICLE	IF	CITATIONS
1	Correlating genotype with phenotype using CFTR-mediated whole-cell Cl <sup>-</sup> currents in human nasal epithelial cells. <i>Journal of Physiology</i> , 2022, 600, 1515-1531.	1.3	14
2	Inflammation biomarkers in sputum for clinical trials in cystic fibrosis: current understanding and gaps in knowledge. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 691-706.	0.3	8
3	Vardenafil increases intracellular accumulation of the most prevalent mutant CFTR in human bronchial epithelial cells. <i>Biology Open</i> , 2020, 9, .	0.6	1
4	Lung immunoglobulin A immunity dysregulation in cystic fibrosis. <i>EBioMedicine</i> , 2020, 60, 102974.	2.7	22
5	Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosis. <i>PLoS ONE</i> , 2019, 14, e0219182.	1.1	21
6	Airway surface liquid acidification initiates host defense abnormalities in Cystic Fibrosis. <i>Scientific Reports</i> , 2019, 9, 6516.	1.6	61
7	Vardenafil reduces macrophage pro-inflammatory overresponses in cystic fibrosis through PDE5- and CFTR-dependent mechanisms. <i>Clinical Science</i> , 2017, 131, 1107-1121.	1.8	13
8	In vitro acute and developmental neurotoxicity screening: an overview of cellular platforms and high-throughput technical possibilities. <i>Archives of Toxicology</i> , 2017, 91, 1-33.	1.9	132
9	Azithromycin Attenuates Pseudomonas-Induced Lung Inflammation by Targeting Bacterial Proteins Secreted in the Cultured Medium. <i>Frontiers in Immunology</i> , 2016, 7, 499.	2.2	10
10	Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives. <i>Clinical Pharmacology: Advances and Applications</i> , 2016, Volume 8, 127-140.	0.8	35
11	Strategies in early clinical development for the treatment of basic defects of cystic fibrosis. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 423-436.	1.9	18
12	Resveratrol increases F508del-CFTR dependent salivary secretion in cystic fibrosis mice. <i>Biology Open</i> , 2015, 4, 929-936.	0.6	18
13	Lung inflammation in cystic fibrosis: Pathogenesis and novel therapies. <i>Clinical Biochemistry</i> , 2014, 47, 539-546.	0.8	45
14	Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanism. <i>British Journal of Pharmacology</i> , 2014, 171, 4831-4849.	2.7	26
15	Dysregulated Proinflammatory and Fibrogenic Phenotype of Fibroblasts in Cystic Fibrosis. <i>PLoS ONE</i> , 2013, 8, e64341.	1.1	31
16	Correction of Chloride Transport and Mislocalization of CFTR Protein by Vardenafil in the Gastrointestinal Tract of Cystic Fibrosis Mice. <i>PLoS ONE</i> , 2013, 8, e77314.	1.1	21
17	Cystic fibrosis: Insight into CFTR pathophysiology and pharmacotherapy. <i>Clinical Biochemistry</i> , 2012, 45, 1132-1144.	0.8	119
18	PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis. <i>Frontiers in Pharmacology</i> , 2012, 3, 167.	1.6	27

#	ARTICLE	IF	CITATIONS
19	Comparative Variability of Nasal Potential Difference Measurements in Human and Mice. <i>Open Journal of Respiratory Diseases</i> , 2012, 02, 43-56.	0.1	9
20	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. <i>Nature Chemical Biology</i> , 2010, 6, 25-33.	3.9	237
21	A Cystic Fibrosis Respiratory Epithelial Cell Chronically Treated by Miglustat Acquires a Non-“Cystic Fibrosis”-Like Phenotype. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2009, 41, 217-225.	1.4	54
22	Stimulation of salivary secretion in vivo by CFTR potentiators in <i>Cftr</i> <sup>+/+</sup> and <i>Cftr</i> <sup>ΔF508/ΔF508</sup> mice. <i>Journal of Cystic Fibrosis</i> , 2008, 7, 128-133.	0.3	15
23	Parallel Improvement of Sodium and Chloride Transport Defects by Miglustat ( <i>n</i> -Butyldeoxyjirimicin) in Cystic Fibrosis Epithelial Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 325, 1016-1023.	1.3	45
24	Discovery of $\beta$ -Aminoazaheterocycle-Methylglyoxal Adducts as a New Class of High-Affinity Inhibitors of Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channels. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 1023-1035.	1.3	16
25	Rescue of functional $\Delta$ F508-CFTR channels in cystic fibrosis epithelial cells by the $\beta$ -glucosidase inhibitor miglustat. <i>FEBS Letters</i> , 2006, 580, 2081-2086.	1.3	123
26	Pharmacological profile of inhibition of the chloride channels activated by extracellular acid in cultured rat Sertoli cells. <i>Reproduction, Nutrition, Development</i> , 2006, 46, 241-255.	1.9	13
27	Discovery of Pyrrolo[2,3- <i>b</i> ]pyrazines Derivatives as Submicromolar Affinity Activators of Wild Type, G551D, and $\Delta$ F508del Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channels. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 349-359.	1.3	39
28	Emerging Roles of microRNAs in Cystic Fibrosis – From Pathogenesis to Development of New Therapies. , 0, , .		2